Welcome to our dedicated page for Cellectis SEC filings (Ticker: CLLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cellectis S.A. (CLLS) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer. Cellectis files its annual report on Form 20-F and furnishes current information on Form 6-K, which often include press releases, interim financial reports, and R&D presentations related to its gene-editing and cell therapy programs.
Through recent Form 6-K filings, Cellectis has submitted materials such as press releases announcing clinical data for lasme-cel (UCART22) in the BALLI-01 trial and eti-cel (UCART20x22) in the NATHALI-01 trial, technology updates on circular single-stranded DNA (CssDNA) for non-viral gene insertion, and details from its Investors R&D Day. Other 6-Ks have incorporated interim financial reports, including information on revenues, research and development expenses, and cash, cash equivalents, and fixed-term deposits.
Because Cellectis uses Form 20-F, investors can look to that filing for comprehensive annual information on its business, risk factors, financial statements, and governance. The series of Form 6-K reports complements the annual filing by providing more frequent updates on clinical progress, collaborations, arbitration outcomes, and capital markets activity.
On Stock Titan, these filings are paired with AI-powered summaries that explain the key points of each document in accessible language. Users can quickly understand what a particular 6-K or 20-F means for Cellectis’ allogeneic CAR-T pipeline, gene-editing platform, partnerships, and financial profile, without having to read every page of the original filing. Real-time updates from EDGAR help ensure that new Cellectis filings, including any future registration statements or amendments, are available as they are posted.
Cellectis S.A. (Nasdaq: CLLS) filed a Form 6-K to disclose outcomes of its 26 June 2025 Combined General Meeting of Shareholders and subsequent Board re-composition. The filing formally incorporates the voting tally (Exhibit 99.1) and the accompanying press release (Exhibit 99.2) into several active U.S. shelf and equity compensation registration statements.
Board and Audit Committee changes: Shareholders elected André Muller to the Board with immediate effect. Concurrently, the mandate of Axel-Sven Malkomes lapsed and the previously announced resignation of Pierre Bastid became effective. Following these departures, the Board re-constituted its Audit Committee, naming Mr. Muller as Chair alongside Donald Bergstrom and Rainer Boehm. The company states that all three members meet both Nasdaq Global Market and SEC Rule 10A-3 independence criteria, ensuring continued compliance with U.S. listing requirements.
No financial statements, operational updates, or transaction details were provided in this submission. The report is limited to corporate governance matters and does not indicate any anticipated impact on Cellectis’ financial performance or strategic direction.